ANPARIO PLC - Final Results for the twelve months to 31 December 2025

Anpario PLC’s FY2025 investor update highlighted record financial results, with revenue up 24%, gross profit rising 34%, adjusted EBITDA increasing 38% to £9.6 million, and EBITDA margins improving to 20.4%, reflecting a stronger product mix, higher-margin sales and the first full-year contribution from the Bio-Vet acquisition. The company also delivered 33% growth in adjusted diluted EPS, strong cash generation and an 11% increase in the dividend, reinforcing confidence in earnings quality, cash flow and balance sheet strength. Management pointed to robust company performance across Asia, the Americas and Europe, with particularly strong organic growth in the Americas and continued momentum from flagship products including Orego-Stim, Optomega and newer launches such as Amplify. The Bio-Vet integration is progressing ahead of expectations, expanding Anpario’s dairy, probiotics and US manufacturing capabilities while creating cross-selling opportunities and supporting its long-term growth strategy. Although trading in the Middle East and Brazil remains mixed, the group said its order book, pipeline and business development activity remain healthy, with multiple opportunities across key regions and species. Despite ongoing geopolitical and logistics risks, Anpario said it is successfully managing costs, protecting margins and remains confident in its outlook, supported by geographic diversification, operational scalability and a disciplined acquisition strategy.